在早期帕金森病中改善无动于衷
A Castrioto1, E Schmitt2, M Anheim3,4,5
1Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38000, Grenoble, France. acastrioto@chu-grenoble.fr.
NPJ Parkinson's disease
|April 24, 2025
概括
多巴胺治疗在四年内改善了早期帕金森病 (PD) 患者的冷漠. 这种改善与减少焦虑和增加高多巴胺行为有关,证实了对激励性冷漠的治疗益处.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 漠不关心是帕金森病 (PD) 中一个显著的,致残的症状.
- 多巴胺治疗PD无动力的疗效是可变的,并受到疾病阶段,无动力类型和安慰剂效应的影响.
- 了解多巴胺疗法对早期PD无动于衷和相关神经精神症状的长期影响至关重要.
研究的目的:
- 为了评估长度变化无动于衷的 de novo,药物原始的帕金森病患者在多巴胺治疗开始后的四年内.
- 评估多巴胺治疗对其他神经精神病症状的影响,包括焦虑和高多巴胺行为.
主要方法:
- 一组86名de novo,未经药物治疗的帕金森病患者被跟踪了4年.
- 在基线和4年随访期间评估了冷漠和其他神经精神症状.
- 进行统计分析以确定症状的变化及其关联.
主要成果:
- 在4年随访期间 (p=0.002) 观察到无动于衷的显著改善,主要是由于基线无动于衷的改善 (p=0.001).
- 多巴胺治疗与焦虑的显著改善有关 (p=0.001).
- 超多巴胺行为增加,包括夜间过度活跃和随后的白天嗜睡 (分别p=0.001和p<0.001),无论基线无动于衷.
结论:
- 多巴胺治疗在改善早期帕金森病的动机性冷漠方面表现出有效性.
- 治疗也对焦虑症状产生积极影响,并与高多巴胺作用的副作用有关.
- 这些发现支持使用多巴氨基疗法在早期PD患者的现实环境中管理冷漠.
相关概念视频
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128


